Evommune's EVO756 fails primary endpoint in Phase 2b urticaria trial

Evommune, Inc. announced on June 29, 2026 that its Phase 2b trial of EVO756 in moderate-to-severe chronic spontaneous urticaria (CSU) did not hit its primary goal. The study did not meet the primary endpoint of mean change in a patient's Urticaria Activity Score over seven days (UAS7) at 12 weeks at any dose.¹

The trial tested oral MRGPRX2 antagonist EVO756 in patients whose CSU had not responded to antihistamines. It enrolled 160 such patients across the United States, Europe, Canada and Japan, with participants receiving one of three active dose regimens or placebo.¹

Chief Medical Officer Eugene Bauer said the drug had shown earlier promise elsewhere. He noted that EVO756 had previously produced positive Phase 2 results in chronic inducible urticaria and had demonstrated clear target engagement in a Phase 1 study, but said the lack of efficacy at Week 12 in this trial does not support further work on EVO756 for CSU.¹ He added that the Phase 2b trial confirmed doses that were safe and well tolerated, supporting further studies in other indications.¹

Per the 8-K filing, Evommune plans to cease development of EVO756 for CSU based on these results, while continuing to evaluate the drug in additional indications.¹

CEO Luis Peña said the company remains on track to report top-line Phase 2b data for EVO756 in atopic dermatitis in the third quarter of 2026, and has begun screening patients for a Phase 2b migraine prophylaxis trial, with dosing expected to start soon.¹ He also said the company recently reported positive Phase 2a proof-of-concept results for its IL-18BP fusion protein EVO301 in atopic dermatitis and plans to advance that program into a Phase 2b trial.¹ Peña said the company's cash position is expected to support operations through 2028.¹